Antibody Production Market worth $2.572 BN by 2019, According to a New Study on ASDReports

Thursday 7 May 2015, Amsterdam

The report, now available on ASDReports, “Antibody Production Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by End-User (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis & Global Forecast to 2019” analyzes and studies the major market drivers, restraints/challenges, and opportunities.

This report studies the global antibody production market for the forecast period of 2014 to 2019. This market is expected to reach $2.572 Billion by 2019 from $1.425 Billion in 2014, and is poised to grow at a CAGR of 12.5% during the forecast period.

The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions.

Based on products, the global market is categorized into equipment and consumables. In 2014, the consumables segment accounted for a major share of the antibody production market.

On the basis of types, this market is segmented into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for a major share of the antibody production market.

Based on technologies, the market is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for a major share of the antibody production market.

On the basis of end users, the market is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. In 2014, the biotechnology and pharmaceutical companies segment accounted for a major share of the antibody production market.

On the basis of regions, the market is divided into North America, Europe, Asia, and the Rest of the World (RoW). The Rest of the World region comprises Latin America, Pacific countries, and Middle East and Africa. In 2014, North America accounted for the largest share of the antibody production market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies offering antibody productions.

Over the years, the demand for production of antibodies is likely to increase owing to the rising demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market.

Some of the major players in the global antibody production market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany).